Post-marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Pfizer
- 09 Feb 2018 Planned End Date changed from 31 Dec 2017 to 17 Feb 2018.
- 09 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 31 Dec 2017.
- 27 Mar 2017 Status changed from not yet recruiting to active, no longer recruiting.